Abstract
The problem of the diabetic foot is one of the most serious complications of diabetes mellitus. There is still an active search for medicines (drugs) that could be used in the complex treatment of trophic lesions in diabetic foot. The period before the development and launch of the drug into the pharmaceutical market need to make marketing research aimed at ensuring that the future drug is competitive.
 The purpose of the work was to analyze the market of dermatological drugs for the treatment of trophic ulcers in order to determine the marketing opportunities for domestic producers.
 The research objects were active pharmaceutical ingredients (APIs), which are part of the dermatological registered drugs in Ukraine. Materials for research were official sources of information about drugs registered in Ukraine. Marketing analytical methods were used. To determine the level of tension between manufacturers and the same product, the coefficient of tension.
 Number of D preparations registered in Ukraine ‒ 452 trade names (January 2018) was established. Medicines wich prodused by Ukraine are slightly higher (55.3%). In groups D01, D03, D06, D07 and D08 the highest number of APIs is determined, which is 25, 36, 33, 29 and 30, respectively.
 Part API is contained in the drug in combination with other API. In the D01 group, only a small amount of API ‒ 7 is present in combination with other substances, and in group D02 ‒ 6, certain APIs are part of the combined drug. In preparations of D03 4 API are in combination. In group D06, 12 APIs are contained in combination drugs. Most of the established API groups D07 (13) are found in the drug in combination. In the D08 group, part of the API (8) is part of a combined drug. There is a combination of APIs antiseptic or antimicrobial activity, anti-inflammatory effect, local anesthetic and wound healing effect. According to the results of the calculation of the tension indices between the manufacturers of analogues of drugs in group D, the highest competition (Kvi ≥ 0.800) was observed in the groups D01 and D03 (for 4 drugs with Kvi ≥ 0.800), D06 (3 drugs), D07 (8 drugs), D08 (7 drugs). An analysis of the competitiveness of analogue manufacturers has shown that Ukrainian manufacturers are not sufficiently competing in the production of modern analogues of dermatological drugs.
Highlights
The problem of the diabetic foot is one of the most serious complications of diabetes mellitus
There is still an active search for medicines that could be used in the complex treatment of trophic lesions in diabetic foot
The study includes an assessment of the feasibility of a drug, the evaluation of the competitiveness of the drug; market research from the standpoint of a competitive structure [4]
Summary
The problem of the diabetic foot is one of the most serious complications of diabetes mellitus. The disease of the limbs affects almost 6% of people with diabetes mellitus, and includes infection, ulcers or destruction of foot tissues [1]. This worsens the quality of life of patients and affects labor and social activity of a person and causes a significant financial burden on the patient and on health care and society as a whole [2]. The period before the development and launch of the drug into the pharmaceutical market is characterized by a large volume of marketing research aimed at ensuring that the future drug is competitive. The purpose of the work was to analyze the market of dermatological drugs for the treatment of trophic ulcers in order to determine the marketing opportunities for domestic producers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
